Sexually dimorphic association of circulating plasminogen activator inhibitor-1 levels and body mass index with cerebrospinal fluid biomarkers of Alzheimer’s pathology in preclinical Alzheimer’s disease

Manuscript Number: 

22-0686R1

Author(s): 
Emily Eruysal, Costantino Iadecola, Makoto Ishii, Hooman Kamel, Lisa Ravdin, Cenai Zhang

Disclosures

Emily Eruysal

  • Nothing to Disclose

Costantino Iadecola

  • Consulting Fees:
    SAB member, Broadiview Ventures, non-profit

Makoto Ishii

  • Equity:
    Regeneron Pharmaceuticals - private stock ownership only (Regeneron is not involved in my research in any capacity, and I have not received any other funding/consultation fees, etc. from Regeneron)

Hooman Kamel

  • Consulting Fees:
    Dr. Kamel serves as a PI for the NIH-funded ARCADIA trial (NINDS U01NS095869), which receives in-kind study drug from the BMS-Pfizer Alliance for Eliquis® and ancillary study support from Roche Diagnostics; as Deputy Editor for JAMA Neurology; on clinical trial steering/executive committees for Medtronic, Janssen, and Javelin Medical; and on endpoint adjudication committees for AstraZeneca, Novo Nordisk, and Boehringer Ingelheim. He has an ownership interest in TETMedical, Inc.
    Equity:
    Dr. Kamel serves as a PI for the NIH-funded ARCADIA trial (NINDS U01NS095869), which receives in-kind study drug from the BMS-Pfizer Alliance for Eliquis® and ancillary study support from Roche Diagnostics; as Deputy Editor for JAMA Neurology; on clinical trial steering/executive committees for Medtronic, Janssen, and Javelin Medical; and on endpoint adjudication committees for AstraZeneca, Novo Nordisk, and Boehringer Ingelheim. He has an ownership interest in TETMedical, Inc.

Lisa Ravdin

  • Nothing to Disclose

Cenai Zhang

  • Nothing to Disclose